Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Setubal – page 45

664 clinical trials in Setubal, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Setubal at a glance
664
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

664 trials in Setubal

Open in trial search

Huntington's disease

Not recruiting

Study on the Safety and Efficacy of Tominersen for Patients with Prodromal and Early Manifest Huntington's Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Tominersen
  • Sponsor:F. Hoffmann-La Roche AG

Study on Acalabrutinib with Drug Combination for Patients 75 and Older with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Daiichi Sankyo Inc.

Plasma cell myeloma

Not recruiting

Study Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Mantle cell lymphoma

Not recruiting

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

Study Comparing Pirtobrutinib to Bendamustine and Rituximab for Untreated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

Study on Setrusumab for Patients with Osteogenesis Imperfecta (Brittle Bone Disease)

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Setrusumab
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Study of Tarlatamab for Patients with Limited-Stage Small-Cell Lung Cancer After Chemoradiotherapy

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Amgen Inc.

Study of Ibrutinib and Rituximab for Patients with Untreated Marginal Zone Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Association International Extranodal Lymphoma Study Group (IELSG)

Study of TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Not Undergoing Radical Cystectomy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Pirtobrutinib vs. Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Loxo Oncology Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Setubal

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking studies focusing on cardiovascular disease prevention and treatment, including innovative approaches to reduce major cardiovascular events and stroke prevention in patients with atrial fibrillation.

  • Lipoprotein management studies
  • Stroke prevention therapies
  • Atherosclerotic disease prevention

Research aims to evaluate new therapeutic options for reducing cardiovascular risks and improving patient outcomes.

02 Neurological Disorders

Clinical investigations targeting migraine management, including specialized studies for menstrual migraine prevention and acute treatment approaches.

  • Preventive migraine treatments
  • Acute migraine interventions
  • Gender-specific migraine studies

These trials explore innovative therapeutic solutions for various types of migraines.

03 Oncology Research

Advanced studies in breast cancer and non-small cell lung cancer treatments, focusing on targeted therapies and innovative treatment combinations.

  • Hormone receptor-positive breast cancer
  • Metastatic cancer treatments
  • Immunotherapy combinations

Research focuses on developing more effective treatments for various cancer types.

04 Autoimmune Conditions

Comprehensive research into systemic lupus erythematosus and related conditions, including specialized studies for lupus nephritis.

  • Lupus treatments
  • Kidney disease management
  • Chronic urticaria studies

Trials aim to improve treatment options for patients with autoimmune disorders.

05 Metabolic Disorders

Innovative research on type 2 diabetes complications, particularly focusing on diabetic retinopathy and its progression.

  • Diabetic eye disease
  • Glycemic control studies
  • Long-term disease management

Studies evaluate new approaches to managing diabetes-related complications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.